<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798966</url>
  </required_header>
  <id_info>
    <org_study_id>TF-1111</org_study_id>
    <nct_id>NCT01798966</nct_id>
  </id_info>
  <brief_title>Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease</brief_title>
  <official_title>The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sensimed AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sensimed AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Thyroid Eye Disease (TED) often have enlarged extraocular muscles and higher
      orbital fat contents due to their disease process. The confined space of the orbit cannot
      hold the enlarged orbital contents creating a forward displacement and/or compression of the
      globe with a rise in intraocular pressure (IOP). Many of these patients undergo surgical
      decompression, a procedure that fractures orbital bones, in order to allow more space for the
      enlarged orbital contents to occupy. To date, there is no data that shows intraocular
      patterns over a 24-hour period in patients with mechanical compression on the globe as in
      TED. It is not know if the pattern of IOP is more consistent with normal IOP patterns,
      glaucomatous patterns, or perhaps completely different then either. The goal of this project
      is to investigate patterns of IOP in patients requiring orbital decompression because of
      orbital congestion. Changes in IOP during a 24-hour period will be studied with a
      contact-lens embedded sensor that provides continuous data. This device has previously been
      investigated and shown to be safe and well-tolerated. Monitoring the pattern in these
      patients will allow us to compare Thyroid TED patterns of IOP with those of normal and
      glaucomatous patients. Also, testing these patients before and after orbital decompression
      surgery will allow characterization of how intraocular pressure changes once the mechanical
      compression on the globe is relieved.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IOP Before and After Orbital Decompression Surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>To investigate the difference in SENSIMED Triggerfish output during transition from wake to sleep states before and after orbital decompression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP Patterns</measure>
    <time_frame>24 hours</time_frame>
    <description>The pattern of IOP in patients with TED will be compared with the pattern of IOP readings in normal subjects as well as glaucomatous patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>4 days</time_frame>
    <description>Safety will be evaluated throughout the duration of the study by collecting all adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Thyroid Eye Disease</condition>
  <arm_group>
    <arm_group_label>SENSIMED Triggerfish</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sensimed Triggerfish device will be worn by each subject for 24h</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SENSIMED Triggerfish</intervention_name>
    <arm_group_label>SENSIMED Triggerfish</arm_group_label>
    <other_name>Contact lens sensor intented to continuously record IOP pattern for up to 24 hours</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to comply with the study procedures

          -  18-80 years old

          -  Subjects diagnosed with Thyroid Eye Disease based on both endocrinology studies
             showing autoimmune dysfunction consistent with Graves' Disease as well as orbital
             imaging studies manifesting characteristics consistent with Thyroid Eye Disease.

          -  Ability to understand the character and individual consequences of the study

          -  Subject has consented to be in the trial

        Exclusion Criteria:

          -  Subjects with contraindications for wearing contact lenses

          -  Severe ocular surface disease

          -  Keratoconus or other corneal abnormality

          -  Severe ocular inflammation

          -  Full frame metal glasses during SENSIMED Triggerfish® monitoring

          -  Known hypersensitivity to silicone, plaster or ocular anesthesia (proparacaine)

          -  Simultaneous participation in other clinical studies

          -  Diagnosis of glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald O Kikkawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiley Eye Center, University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0496</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2013</study_first_submitted>
  <study_first_submitted_qc>February 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2013</study_first_posted>
  <results_first_submitted>December 4, 2014</results_first_submitted>
  <results_first_submitted_qc>February 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2015</results_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SENSIMED Triggerfish</title>
          <description>All patients included in the device group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SENSIMED Triggerfish</title>
          <description>All patients included in the device group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tolerability of CLS</title>
          <description>Subjective comfort level using a number between 0-10 with values ranging from 0 (no discomfort) to 10 (very severe discomfort)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in IOP Before and After Orbital Decompression Surgery</title>
        <description>To investigate the difference in SENSIMED Triggerfish output during transition from wake to sleep states before and after orbital decompression</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SENSIMED Triggerfish</title>
            <description>SENSIMED Triggerfish worn for 24h</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IOP Before and After Orbital Decompression Surgery</title>
          <description>To investigate the difference in SENSIMED Triggerfish output during transition from wake to sleep states before and after orbital decompression</description>
          <units>mVEq (Sensismed Triggerfish output unit)</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IOP Patterns</title>
        <description>The pattern of IOP in patients with TED will be compared with the pattern of IOP readings in normal subjects as well as glaucomatous patients</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SENSIMED Triggerfish</title>
            <description>All patients included in the device group</description>
          </group>
        </group_list>
        <measure>
          <title>IOP Patterns</title>
          <description>The pattern of IOP in patients with TED will be compared with the pattern of IOP readings in normal subjects as well as glaucomatous patients</description>
          <units>mvEq</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.2" spread="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events and Serious Adverse Events</title>
        <description>Safety will be evaluated throughout the duration of the study by collecting all adverse events</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SENSIMED Triggerfish</title>
            <description>SENSIMED Triggerfish worn for 24h</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events and Serious Adverse Events</title>
          <description>Safety will be evaluated throughout the duration of the study by collecting all adverse events</description>
          <units>Number of AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From inform consent signature to 30 days after last exposure to device</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SENSIMED Triggerfish</title>
          <description>All patients included in the device group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Mild blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mild hyperemia and palpebral conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Superficial Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anjali Parekh</name_or_title>
      <organization>Hamilton Glaucoma center</organization>
      <phone>+1858 822-1553</phone>
      <email>anjalism@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

